Literature DB >> 10491013

DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

A K Larsen1, C Gobert.   

Abstract

Mammalian DNA topoisomerase I is a multifunctional enzyme which is essential for embryonal development. In addition to its classical DNA nicking-closing activities which are needed for relaxation of supercoiled DNA, topoisomerase I can phosphorylate certain splicing factors. The enzyme is also involved in transcriptional regulation through its ability to associate with other proteins in the TFIID-, and possibly TFIIH-, transcription complexes, and is implicated in the recognition of DNA lesions. Finally, topoisomerase I is a recombinase which can mediate illegitimate recombination. A crucial reaction intermediate during relaxation of DNA is the formation of a DNA-topoisomerase I complex (the cleavable complex) where topoisomerase I is covalently linked to a 3 -end of DNA thereby creating a single stranded DNA break. Cleavable complexes are also formed in the vicinity of DNA lesions and in the presence of the antitumor agent, camptothecin. While formation of cleavable complexes may be necessary for the initial stages of the DNA damage response, these complexes are also potentially dangerous to the cell due to their ability to mediate illegitimate recombination, which can lead to genomic instability and oncogenesis. Thus the levels and stability of these complexes have to be strictly regulated. This is obtained by maintaining the enzyme levels relatively constant, by limiting the stability of the cleavable complexes through physical interaction with the oncogene suppressor protein p53 and by degradation of the topoisomerase I by the proteasome system. Emerging evidence suggest that these regulatory functions are perturbed in tumor cells, explaining at the same time why topoisomerase I activities so often are increased in certain human tumors, and why these cells are sensitized to the cytotoxic effects of camptothecins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491013     DOI: 10.1053/paor.1999.0209

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  84 in total

1.  Association of crossover points with topoisomerase I cleavage sites: a model for nonhomologous recombination.

Authors:  P Bullock; J J Champoux; M Botchan
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

2.  Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae.

Authors:  I B Castaño; P M Brzoska; B U Sadoff; H Chen; M F Christman
Journal:  Genes Dev       Date:  1996-10-15       Impact factor: 11.361

3.  Association of eukaryotic DNA topoisomerase I with nucleosomes and chromosomal proteins.

Authors:  K Javaherian; L F Liu
Journal:  Nucleic Acids Res       Date:  1983-01-25       Impact factor: 16.971

4.  Role of DNA topoisomerase I in the transcription of supercoiled rRNA gene.

Authors:  L C Garg; S DiAngelo; S T Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro.

Authors:  L Yang; M S Wold; J J Li; T J Kelly; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

6.  DNA-topoisomerase I, a new target for the treatment of neuroblastoma.

Authors:  G Vassal; C Pondarré; C Cappelli; M J Terrier-Lacombe; I Boland; J Morizet; J Bénard; A M Vénuat; P Ardouin; O Hartmann; A Gouyette
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

7.  Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.

Authors:  H L McLeod; F Douglas; M Oates; R P Symonds; D Prakash; A G van der Zee; S B Kaye; R Brown; W N Keith
Journal:  Int J Cancer       Date:  1994-12-01       Impact factor: 7.396

Review 8.  Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

Authors:  A K Larsen; A Skladanowski
Journal:  Biochim Biophys Acta       Date:  1998-10-01

9.  Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I.

Authors:  F Rossi; E Labourier; T Forné; G Divita; J Derancourt; J F Riou; E Antoine; G Cathala; C Brunel; J Tazi
Journal:  Nature       Date:  1996-05-02       Impact factor: 49.962

10.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization.

Authors:  T Uemura; M Yanagida
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more
  13 in total

1.  Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.

Authors:  Anindya Goswami; Shirley Qiu; Thomas S Dexheimer; Padhma Ranganathan; Ravshan Burikhanov; Yves Pommier; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

2.  Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.

Authors:  Mary R Stahley; James T Stivers
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

3.  DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.

Authors:  Antoine Mialon; Matti Sankinen; Henrik Söderström; Teemu T Junttila; Tim Holmström; Riku Koivusalo; Anastassios C Papageorgiou; Randall S Johnson; Sakari Hietanen; Klaus Elenius; Jukka Westermarck
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

4.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target.

Authors:  S Horvath; B Zhang; M Carlson; K V Lu; S Zhu; R M Felciano; M F Laurance; W Zhao; S Qi; Z Chen; Y Lee; A C Scheck; L M Liau; H Wu; D H Geschwind; P G Febbo; H I Kornblum; T F Cloughesy; S F Nelson; P S Mischel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

5.  Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.

Authors:  Shyamal D Desai; Hui Zhang; Alexandra Rodriguez-Bauman; Jin-Ming Yang; Xiaohua Wu; Murugesan K Gounder; Eric H Rubin; Leroy F Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

Review 6.  The involvement of DNA-damage and -repair defects in neurological dysfunction.

Authors:  Avanti Kulkarni; David M Wilson
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

7.  Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants.

Authors:  Anja Restle; Martin Färber; Cindy Baumann; Michael Böhringer; Karl Heinz Scheidtmann; Carsten Müller-Tidow; Lisa Wiesmüller
Journal:  Nucleic Acids Res       Date:  2008-08-12       Impact factor: 16.971

8.  Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer.

Authors:  Misato Ogino; Takaaki Fujii; Yuko Nakazawa; Toru Higuchi; Yukio Koibuchi; Tetsunari Oyama; Jun Horiguchi; Ken Shirabe
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

9.  The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.

Authors:  Keya Bandyopadhyay; Pingchuan Li; Ruth A Gjerset
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

10.  Gene disruption of the DNA topoisomerase IB small subunit induces a non-viable phenotype in the hemoflagellate Leishmania major.

Authors:  Rafael Balaña-Fouce; Carlos García-Estrada; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  BMC Microbiol       Date:  2008-07-08       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.